SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disea...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer Milan
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689754/ |
| id |
pubmed-4689754 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-46897542015-12-31 SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma Rueda Domínguez, A. Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. Clinical Guides in Oncology Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Springer Milan 2015-10-26 2015 /pmc/articles/PMC4689754/ /pubmed/26497354 http://dx.doi.org/10.1007/s12094-015-1429-1 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Rueda Domínguez, A. Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. |
| spellingShingle |
Rueda Domínguez, A. Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| author_facet |
Rueda Domínguez, A. Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. |
| author_sort |
Rueda Domínguez, A. |
| title |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title_short |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title_full |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title_fullStr |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title_full_unstemmed |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title_sort |
seom clinical guidelines for the treatment of hodgkin’s lymphoma |
| description |
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
|
| publisher |
Springer Milan |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689754/ |
| _version_ |
1613516251552808960 |